Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
29.98 USD | -3.20% | +5.19% | 0.00% |
May. 14 | Goldman Sachs Upgrades CG Oncology to Buy From Neutral With $50 Price Target | MT |
May. 09 | CG Oncology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Financials (USD)
Sales 2024 * | 1.66M | Sales 2025 * | 8.78M | Capitalization | 2B |
---|---|---|---|---|---|
Net income 2024 * | -88M | Net income 2025 * | -112M | EV / Sales 2024 * | 1,132 x |
Net cash position 2024 * | 117M | Net cash position 2025 * | 134M | EV / Sales 2025 * | 212 x |
P/E ratio 2024 * |
-17.6
x | P/E ratio 2025 * |
-14.8
x | Employees | 61 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 92.95% |
1 day | -3.20% | ||
1 week | +5.19% | ||
Current month | -25.40% | ||
1 month | -15.12% | ||
3 months | -37.45% |
Managers | Title | Age | Since |
---|---|---|---|
Arthur Kuan
CEO | Chief Executive Officer | 34 | 17-11-29 |
Ambaw Bellete
PSD | President | 54 | 23-06-30 |
Vijay Kasturi
CTO | Chief Tech/Sci/R&D Officer | 57 | 23-08-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Susan Graf
BRD | Director/Board Member | 52 | Nov. 19 |
Leonard Post
BRD | Director/Board Member | 72 | 18-10-21 |
Victor Tong
BRD | Director/Board Member | 41 | 23-06-30 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-17 | 29.98 | -3.20% | 603,246 |
24-05-16 | 30.97 | +10.57% | 882,035 |
24-05-15 | 28.01 | +2.53% | 910,276 |
24-05-14 | 27.32 | +5.73% | 1,448,007 |
24-05-13 | 25.84 | -9.33% | 948,639 |
Delayed Quote Nasdaq, May 17, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
0.00% | 2B | |
-0.09% | 42.12B | |
+49.62% | 42.05B | |
-4.96% | 29.18B | |
+11.18% | 26.02B | |
-21.95% | 18.9B | |
+8.61% | 13.21B | |
+24.73% | 12.17B | |
+28.31% | 12.16B | |
-6.26% | 11.42B |
- Stock Market
- Equities
- CGON Stock